Johnson&Johnson-强生-SWOT-2010

Johnson&JohnsonCompanyProfilePublicationDate:8Sep2010:[phone]t:[phone]t:[phone]f:[phone]f:[phone]f:[phone]e:[e-mail]:[e-mail]:[e-mail]onitorisaleadingbusinessinformationcompanyspecializinginindustryanalysis.Throughitsproprietarydatabasesandwealthofexpertise,Datamonitorprovidesclientswithunbiasedexpertanalysisandindepthforecastsforsixindustrysectors:Healthcare,Technology,Automotive,Energy,ConsumerMarkets,andFinancialServices.ThecompanyalsoadvisesclientsontheimpactthatnewtechnologyandeCommercewillhaveontheirbusinesses.DatamonitormaintainsitsheadquartersinLondon,andregionalofficesinNewYork,Frankfurt,andHongKong.Thecompanyservestheworld'slargest5000companies.Datamonitor'spremiumreportsarebasedonprimaryresearchwithindustrypanelsandconsumers.Wegatherinformationonmarketsegmentation,marketgrowthandpricing,competitorsandproducts.Ourexpertstheninterpretthisdatatoproducedetailedforecastsandactionablerecommendations,helpingyoucreatenewbusinessopportunitiesandideas.Ourseriesofcompany,industryandcountryprofilescomplementsourpremiumproducts,providingtop-levelinformationon10,000companies,2,500industriesand50countries.Whiletheydonotcontainthehighlydetailedbreakdownsfoundinpremiumreports,profilesgiveyouthemostimportantqualitativeandquantitativesummaryinformationyouneed-includingpredictionsandforecasts.AllRightsReserved.Nopartofthispublicationmaybereproduced,storedinaretrievalsystemortransmittedinanyformbyanymeans,electronic,mechanical,photocopying,recordingorotherwise,withoutthepriorpermissionofthepublisher,Datamonitorplc.Thefactsofthisprofilearebelievedtobecorrectatthetimeofpublicationbutcannotbeguaranteed.Pleasenotethatthefindings,conclusionsandrecommendationsthatDatamonitordeliverswillbebasedoninformationgatheredingoodfaithfrombothprimaryandsecondarysources,whoseaccuracywearenotalwaysinapositiontoguarantee.AssuchDatamonitorcanacceptnoliabilitywhateverforactionstakenbasedonanyinformationthatmaysubsequentlyprovetobeincorrect.Johnson&JohnsonPage2©DatamonitorJohnson&JohnsonTABLEOFCONTENTSCompanyOverview..............................................................................................4KeyFacts...............................................................................................................4SWOTAnalysis.....................................................................................................5Johnson&JohnsonPage3©DatamonitorJohnson&JohnsonTABLEOFCONTENTSCOMPANYOVERVIEWJohnson&Johnson(J&J),theworld’sleadingconsumerhealthcompany,isengagedintheR&D,manufactureandsaleofconsumerhealthcareproducts,pharmaceuticalsandmedicaldevicesanddiagnostics.Thecompanyhasmorethan250operatingcompaniesacrosstheworld.ItisheadquarteredinNewBrunswick,NewJerseyandemployed115,500peopleasofDecember31,2009.Thecompanyrecordedrevenuesof$61,897millionduringthefinancialyear(FY)endedDecember2009,adecreaseof2.9%overFY2008.Theoperatingprofitofthecompanywas$15,590millionduringFY2009,adecreaseof2.5%overFY2008.Thenetprofitwas$12,266millioninFY2009,adecreaseof5.3%overFY2008.KEYFACTSJohnson&JohnsonHeadOfficeOneJohnson&JohnsonPlazaNewBrunswickNewJersey08933USA17325240400Phone[phone]Fax(USDMn)DecemberFinancialYearEnd115,500EmployeesJNJNewYorkTickerJohnson&JohnsonPage4©DatamonitorJohnson&JohnsonCompanyOverviewSWOTANALYSISJohnson&Johnson(J&J),theworld’slargestdiversifiedhealthcarecompanyintermsofrevenues,isengagedintheR&D,manufactureandsaleofconsumerhealthcareproducts,pharmaceuticalsandmedicaldevicesanddiagnostics.J&J‘sstrongpresenceindiverseareasofhealthcareandstrongsalesandmarketingcapabilitieshaveenabledittohaveahealthyfinancialposition.However,thefailureoftheproductportfolioinlatestageandlaunchstagepipelinescouldaffectthecompany’srevenuesinnearfuture.WeaknessesStrengthsHighrelianceuponsmallmoleculedrugs,increasingexposuretogenericerosionDiversebusinessofferingForecasttotalrevenuegrowthdespitechallengesLimitedoutputfromin-houseR&DSignificantsalesandmarketingcapabilitiesRobustfinancialpositionThreatsOpportunitiesFailureoflaunchportfoliotodeliverLeveragetherapeuticcoverageofMedicalDevices&DiagnosticsandConsumerHealthdivisionsBroadenpositioninbiologicsLaterthanforecastlaunchofgenericConcertaorInvegaStrengthsDiversebusinessofferingJ&Jrepresentsoneofthemostdiversehealthcarecompanies,bothintermsofitspharmaceuticalportfolio,butalsoduetoitslargeMedicalDevices&Diagnostics(M,D&D)andConsumerHealthdivisions.Thisdiversificationreducesthecompany’sdependenceuponanyoneareaandissettobroadenfurtheracross2008–14.Additionally,withapresenceinawidenumberofhealthcaresegments,J&Jcanchoosetoexpandthosethatofferthegreatestgrowthprospects,ratherthanbeinglimitedtojustoneortwoareasofexpertise.Forecasttotalrevenuegrowthdespitechalle